The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The clinical use of corticosteroids in pregnancy
Open accessAbstract
BACKGROUND: The use of antenatal steroid therapy is common in pregnancy. In early pregnancy, steroids may be used in women for the treatment of recurrent miscarriage or fetal abnormalities such as congenital adrenal hyperplasia. In mid-late pregnancy, the antenatal administration of corticosteroids to expectant mothers in anticipation of preterm birth is one of the most important advances in perinatal medicine; antenatal corticosteroids are now standard care for pregnancies at risk of premature delivery in high- and middle-income countries. The widespread uptake of this therapy is due to a compelling body of evidence demonstrating improved neonatal outcomes following antenatal corticosteroid exposure, stemming most notably from corticosteroid-driven maturation of fetal pulmonary function. As we approach the 50th anniversary of landmark work in this area by Liggins and Howie, it is apparent that much remains to be understood with regards to how we might best apply antenatal corticosteroid therapy to improve pregnancy outcomes at both early and mid to late gestation. METHODS: Drawing on advances in laboratory science, pre-clinical and clinical studies, we performed a narrative review of the scientific literature to provide a timely update on the benefits, risks and uncertainties regarding antenatal corticosteroid use in pregnancy. Three, well-established therapeutic uses of antenatal steroids, namely recurrent miscarriage, congenital adrenal hyperplasia and preterm birth, were selected to frame the review. RESULTS: Even the most well-established antenatal steroid therapies lack the comprehensive pharmacokinetic and dose-response data necessary to optimize dosing regimens. New insights into complex, tissue-specific corticosteroid signalling by genomic-dependent and independent mechanisms have not been used to inform corticosteroid treatment strategies. There is growing evidence that some fetal corticosteroid treatments are either ineffective, or may result in adverse outcomes, in addition to lasting epigenetic changes in a variety of homeostatic mechanisms. Nowhere is the need to better understand the intricacies of corticosteroid therapy better conveyed than in the findings of Althabe and colleagues who recently reported an increase in overall neonatal mortality and maternal morbidity in association with antenatal corticosteroid administration in low-resource settings. CONCLUSIONS: New research to clarify the benefits and potential risks of antenatal corticosteroid therapy is urgently needed, especially with regard to corticosteroid use in low-resource environments. We conclude that there is both significant scope and an urgent need for further research-informed refinement to the use of antenatal corticosteroids in pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preterm labor: One syndrome, many causes
Romero, R., Dey, S. K., & Fisher, S. J. (2014) · Science · doi:10.1126/science.1251816 · Cited by 1,984
DNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 1×
“Protein binding of prednisolone decreases from approximately 95% at plasma concentrations of 200 m g/l to 60–70% at plasma concentrations of 800 m g/l although free prednisolone pharmacokinetics are not thought to be dose dependent (Czock et al. , 2005).”
BackgroundReview: Sex and the human placenta: Mediating differential strategies of fetal growth and survival
Clifton, V. L. (2010) · Placenta · doi:10.1016/j.placenta.2009.11.010 · Cited by 868
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628 · cited 3×
“The cause of congenital adrenal hyperplasia is deficiency in 21-hydroxylase in more than 95% of cases (Merke and Bornstein, 2005).”
Reynolds, R. M. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.012 · Cited by 497
Webster, J. C., Oakley, R. H., Jewell, C. M., & Cidlowski, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121455098 · Cited by 482
Dalziel, S. R., Walker, N. K., Parag, V., Mantell, C., Rea, H. H., Rodgers, A., & Harding, J. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66617-2 · Cited by 461
Murphy, K. E., Hannah, M. E., Willan, A. R., Hewson, S. A., Ohlsson, A., Kelly, E. N., Matthews, S. G., Saigal, S., Asztalos, E., Ross, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61929-7 · Cited by 391
GLUCOCORTICOID AND MINERALOCORTICOID RECEPTORS: Biology and Clinical Relevance
Funder, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.231 · Cited by 320 · cited 2×
“At physiological concentrations, endogenous corticosteroids bind to the MR with 10 times greateraffinityforMRthanGR(Funder,1997).”
Background
Cited by
Wastnedge, E. A. N., Reynolds, R. M., van Boeckel, S. R., Stock, S. J., Denison, F. C., Maybin, J. A., & Critchley, H. O. D. (2021) · Physiological Reviews · doi:10.1152/physrev.00024.2020 · Cited by 636
Self-citationRecurrent pregnancy loss: current perspectives
El Hachem, H., Crepaux, V., May-Panloup, P., Descamps, P., Legendre, G., & Bouet, P.-E. (2017) · International Journal of Women's Health · doi:10.2147/ijwh.s100817 · Cited by 462
Metadata
- Authors
- Kemp, M. W., Newnham, J. P., Challis, J. G., Jobe, A. H., & Stock, S. J.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-20
- Volume
- 22
- Issue
- 2
- Pages
- dmv047
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2262241988
- Cited by
- 216
- References
- 22
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical use of corticosteroids in pregnancy. https://app.cochat.ai/papers/10.1093/humupd/dmv047
- The paper
- Kemp, M. W., Newnham, J. P., Challis, J. G., Jobe, A. H., & Stock, S. J. (2015). The clinical use of corticosteroids in pregnancy. Human Reproduction Update. https://doi.org/10.1093/humupd/dmv047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.